Search results for "From ACP Journal Club"
In uncomplicated, left-sided acute diverticulitis, observation did not differ from antibiotics for recovery
At 6-month follow-up, no differences were found in time to recovery, readmission, development of complications, or mortality in patients assigned to observation or those assigned to antibiotics.
https://gastroenterology.acponline.org/archives/2017/02/24/7.htm
24 Feb 2017
In patients having transjugular intrahepatic portosystemic shunt, rifaximin prevented overt hepatic encephalopathy
Results from a French trial provide the best available evidence to justify using the expensive antibiotic in patients with hepatic encephalopathy associated with transjugular intrahepatic portosystemic shunt, according to an ACP Journal Club commentary.
https://gastroenterology.acponline.org/archives/2021/07/23/7.htm
23 Jul 2021
In C difficile infection, adding IV bezlotoxumab to standard antibiotics reduced recurrence at 12 weeks
A commentary in ACP Journal Club noted that it would be reasonable to consider fidaxomicin or bezlotoxumab in patients at high risk for recurrent Clostridium difficile infection or in those for whom recurrence could have devastating consequences.
https://gastroenterology.acponline.org/archives/2017/05/26/10.htm
26 May 2017
In chronic severe functional constipation, electroacupuncture increased complete spontaneous bowel movements
Patients undergoing electroacupuncture experienced a change from baseline in mean complete spontaneous bowel movements per week during the treatment period, and treatment effects were even greater after patients stopped attending the sessions.
https://gastroenterology.acponline.org/archives/2017/01/27/9.htm
27 Jan 2017
In recurrent C difficile infection, oral FMT capsules have a pooled cure rate of 82% (low-quality evidence)
While the findings of a recent study are promising for oral fecal microbiota transplantation (FMT) capsules to treat patients with recurrent Clostridioides difficile infection, more well-designed trials are needed before routine use, an ACP Journal Club commentary noted.
https://gastroenterology.acponline.org/archives/2021/06/25/8.htm
25 Jun 2021
Any of 4 screening options suggested for screen-naive adults 59 to 70 y with ≥ 3% 15-y risk for colorectal cancer
To balance shared decision making and population health in colorectal cancer screening, as called for in a recent guideline, a viable strategy could include universal, opt-out fecal immunochemical testing starting at age 50 years, a commentary in ACP Journal Club noted.
https://gastroenterology.acponline.org/archives/2020/03/27/11.htm
27 Mar 2020
In persons aged ≥45 y, the mt-sRNA test had 94% sensitivity for colorectal cancer and 46% for advanced adenomas
The results of the industry-funded study support the use of the multitarget stool RNA (mt-sRNA) test for screening, but better adherence will be needed, and it is unclear whether the new test offers any advantages over current stool DNA testing, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2024/02/23/6.htm
23 Feb 2024
Genotypic resistance–guided and medication-guided therapies did not differ for eradicating refractory H pylori
Patients with Helicobacter pylori infection had similar cure rates with resistance-guided and medication-guided therapy, an unexpected finding, according to an ACP Journal Club commentary.
https://gastroenterology.acponline.org/archives/2019/03/22/6.htm
22 Mar 2019
In high-risk patients with acute upper GI bleeding, urgent vs. early endoscopy did not differ for 30-day mortality
While a randomized trial found no better outcomes with endoscopy within six hours of gastroenterology consult, “middle-of-the-night” endoscopy should still be considered for certain higher-risk patients who were excluded from the trial, an ACP Journal Club commentary noted.
https://gastroenterology.acponline.org/archives/2020/08/28/7.htm
28 Aug 2020
In primary care, second-line IBS therapy with amitriptyline vs. placebo reduced symptoms at 6 mo
An ACP Journal Club commentary said the high-quality randomized trial provides pragmatic guidance on amitriptyline dosing in patients with irritable bowel syndrome (IBS), as well as additional support for the drug as an option in primary care after first-line therapies fail.
https://gastroenterology.acponline.org/archives/2024/02/23/7.htm
23 Feb 2024